July 2026 expanded the AI × bio frontier.
On one end, Insilico’s rentosertib entered Phase III - a new milestone for AI-driven drug discovery, and a much tougher test than anything that came before it.
On the other, startup Precigenetics offered a glimpse of something even more tantalizing: AI following the same living cell through time, potentially giving biological models a kind of data they have barely had access to before.
And those were just two of the stories.
Many of us were on vacation. AI × bio was as busy as ever.
Here are 10 developments from July worth catching up on.